Covis Pharma announced the initiation of a phase 3 clinical Study to assess the safety and efficacy of its Asthma Drug Alvesco (ciclesonide) in non-hospitalized patients 12 years of age and older with symptomatic COVID-19. Patient recruitment for the multicenter, randomized, double-blind, placebo-controlled study of Alvesco is underway. The study is being initiated after FDA […]